CagriSema,
does it really help with Weight loss noninferior to tirzepatide 15 mg in obesity treatment?
research showsThe claim that CagriSema produces as much weight loss as tirzepatide was not demonstrated in REDEFINE 4, so it is rated D. The 2026 evidence is a manufacturer regulatory disclosure and press release, not a peer-reviewed original article. The open-label phase 3 trial randomized 809 participants and failed its 84-week noninferiority primary endpoint. Weight loss under the adherence estimand was 23.0% versus 25.5%, and the treatment-regimen estimand was 20.2% versus 23.6%, yielding D with 24 points.
ads claimThe promotional statement that CagriSema works as well as tirzepatide was not established on the prespecified REDEFINE 4 primary endpoint. Isolating the large 23% figure while omitting the noninferiority failure misrepresents the comparative claim.
Useful facts when choosing a product
- CagriSema is an investigational combination of the long-acting amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide, each given at 2.4 mg once weekly by subcutaneous injection.
- REDEFINE 4 was an open-label 84-week head-to-head trial of CagriSema and tirzepatide 15 mg that randomized 809 participants.
- The most common adverse events were gastrointestinal, including nausea, vomiting, diarrhea, and constipation, and were reported as mostly mild to moderate.
- As of verification, the head-to-head result remained a manufacturer disclosure without a peer-reviewed article containing full statistical, discontinuation, and adverse-event tables.
What the research actually shows
The pivotal publication form is a February 23, 2026 Novo Nordisk manufacturer press release filed as a United States SEC Form 6-K regulatory disclosure; a peer-reviewed REDEFINE 4 original article was unpublished as of verification. The open-label phase 3 trial randomized 809 participants and compared CagriSema 2.4/2.4 mg with tirzepatide 15 mg for 84 weeks. The weight-change noninferiority primary endpoint failed. The efficacy estimand assuming adherence was 23.0% versus 25.5%, and the treatment-regimen estimand was 20.2% versus 23.6%. The peer-reviewed 3,417-person REDEFINE 1 trial established weight loss versus placebo but did not test noninferiority to tirzepatide.
Why this is classified as D (24)
A direct 809-person phase 3 comparison failed its prespecified noninferiority primary endpoint, and the public evidence remains a manufacturer regulatory disclosure and press release. This yields D with 24 points.
Counterpoint. A separate large phase 3 trial was positive for weight loss versus placebo, so the absolute effect and the failed comparative claim must be kept distinct. Verdict 1305, which is C with 58 points, addresses cagrilintide alone; verdict 631, which is B with 79 points, addresses tirzepatide; and verdict 841, which is B with 79 points, addresses semaglutide. This D applies only to CagriSema's failed noninferiority claim against tirzepatide.
Rejudgment record. New verdict — The 84-week weight-loss noninferiority primary endpoint failed in an open-label phase 3 trial of 809 randomized participants, and the evidence remains a manufacturer regulatory disclosure and press release without a peer-reviewed original article
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Weight loss noninferior to tirzepatide 15 mg | D | The 84-week noninferiority primary endpoint failed in 809 randomized participants. |
| Weight loss versus placebo | C | REDEFINE 1 was positive, but it is a single manufacturer program and addresses a different comparison. |
| Reduced cardiovascular events or mortality | ? | No completed human trial has yet reported these hard outcomes for CagriSema itself. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Novo Nordisk REDEFINE 4 company announcement No. 13/2026 | Manufacturer press release and SEC Form 6-K regulatory disclosure of an open-label phase 3 head-to-head trial | 809 | Novo Nordisk manufacturer-sponsored trial and disclosure | Primary noninferiority of weight change versus tirzepatide 15 mg at week 84 | The primary endpoint failed. Results were 23.0% versus 25.5% under the adherence estimand and 20.2% versus 23.6% under the treatment-regimen estimand. | Pivotal evidence for the comparative claim, but no peer-reviewed original article |
| Garvey WT et al.; REDEFINE 1 Study Group. 2025 | Peer-reviewed phase 3a randomized double-blind placebo- and component-controlled trial | 2,108 | Novo Nordisk manufacturer-sponsored trial | Weight change and at least 5% weight loss at week 68 | Weight loss versus placebo was positive, but this trial did not test noninferiority to tirzepatide. | Supporting context for absolute weight-loss efficacy |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] CagriSema x weight loss noninferior to tirzepatide 15 mg — Evidence Grade D·24. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/cagrisema-noninferior-to-tirzepatide-weight-loss/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.